Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin-eluting beads - BTG

Drug Profile

Doxorubicin-eluting beads - BTG

Alternative Names: DC Bead; DC Bead LUMI™; DEBDOX; Doxorubicin-loaded DC Bead LUMI™; E7040; Embolic bead; LifePearl; PRECISION Bead

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocompatibles International; Eisai Co Ltd
  • Developer Biocompatibles International; BTG; Eisai Co Ltd; SciClone Pharmaceuticals; Terumo
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Liver cancer; Vascular disorders
  • No development reported Lung cancer

Most Recent Events

  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 12 Mar 2018 BTG and Biocompatabilities International plans a clinical trial for Hepatocellular carcinoma in April 2018 (NCT03452553)
  • 01 Mar 2017 No development reported - Phase-II for liver cancer in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top